Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Vivaldi to lead global therapeutic operations, Greene to serve as CFO
November 15, 2016
By: Kristin Brooks
Managing Editor, Contract Pharma
Biogen has added two members to the executive management team of Bioverativ Inc., Biogen’s planned spin-off focused on the discovery, research, development and commercialization of treatments for hemophilia and other blood disorders. Rogerio Vivaldi, M.D., will serve as executive vice president and chief global therapeutic operations officer, and John T. Greene will serve as executive vice president and chief financial officer. The spin-off is scheduled to be completed in early 2017. “Biogen is committed to positioning Bioverativ for success as it prepares to carry forward our dedication to the hemophilia community,” said George A. Scangos, Ph.D., chief executive officer of Biogen. “Rogerio and John will be instrumental players in that success, alongside the rest of the executive team.” “Rogerio’s expertise in the industry and extensive knowledge of the rare disease space will be critical as we work to deliver transformative medicines to patients,” said John Cox, chief executive officer of Bioverativ. “And, given John’s strong track record of fiscal and operational management across all of the major disciplines within finance, I am confident in his ability to lead our global finance organization and be an excellent representative for our shareholders.” Dr. Vivaldi has more than 20 years of experience developing orphan products, most notably during his tenure at Genzyme Corp., where he lead the company’s rare disease business. Most recently, he served as chief commercial officer at Spark Therapeutics, a gene therapy company, and was co-founder, president and CEO of Minerva Neurosciences. Dr. Vivaldi will be responsible for building and leading all aspects of Bioverativ’s commercial organization, including oversight of sales and marketing for the franchise’s lead products, ELOCTATE and ALPROLIX, extended half-life therapies for the treatment of hemophilia A and hemophilia B, respectively. He will report to Bioverativ CEO John Cox. Mr. Greene joins Bioverativ from Willis Group, plc, where he served as chief financial officer, enhancing business analytics and company performance and helping to execute a merger and acquisition program. Previously, he was chief financial officer for HSBC Holdings. Mr. Greene will be responsible for all financial and fiscal management of Bioverativ’s operations, with oversight for the company’s finance, information technology and technical operations functions. He will also work closely with business development, and research and development to grow the business. He will also report to Mr. Cox.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !